National Health Act (Pharmaceutical Benefits – Early Supply) Amendment December 2011 specification under subsection 84AAA(2) (No. PB 92 of 2011) (Cth)
COMMONWEALTH OF AUSTRALIA
Instrument number PB 92 of 2011
National Health Act (Pharmaceutical Benefits – Early Supply) Amendment December 2011 - specification under subsection 84AAA(2)1
Amendment determination under subsection 84AAA(2) of the National Health Act 1953
I, Adriana Platona, Assistant Secretary, Pharmaceutical Evaluation Branch, Department of Health and Ageing, delegate of the Minister for Health and Ageing, make this Instrument under subsection 84AAA(2) of the National Health Act 1953.
Dated 23 November 2011
ADRIANA PLATONA
Assistant Secretary
Pharmaceutical Evaluation Branch
Department of Health and Ageing
Amendment determination — Pharmaceutical Benefits - Early Supply
1 Name of Instrument
(1) This Instrument is the National Health Act (Pharmaceutical Benefits – Early Supply) Amendment December 2011 - specification under subsection 84AAA(2).
(2) This Instrument may also be cited as No. PB 92 of 2011.
2 Commencement
This Instrument commences on 1 December 2011.
3 Amendment of PB 30 of 2009
Schedule 1 amends the National Health (Pharmaceutical Benefits – Early Supply) Instrument 2009- specification under subsection 84AAA(2), PB 30 of 2009.
Schedule 1 Amendments
Schedule 1, after entry for Clopidogrel with aspirin
insert in the columns in the order indicated:
| Dalteparin | Injection containing dalteparin sodium 7,500 I.U. (anti-Xa) in 0.75 mL single dose pre-filled syringe | Injection | 30 | 5 |
| Injection containing dalteparin sodium 10,000 I.U. (anti-Xa) in 1 mL single dose pre-filled syringe | Injection | 30 | 5 | |
| Injection containing dalteparin sodium 12,500 I.U. (anti-Xa) in 0.5 mL single dose pre-filled syringe | Injection | 30 | 5 | |
| Injection containing dalteparin sodium 15,000 I.U. (anti-Xa) in 0.6 mL single dose pre-filled syringe | Injection | 30 | 5 | |
| Injection containing dalteparin sodium 18,000 I.U. (anti-Xa) in 0.72 mL single dose pre-filled syringe | Injection | 30 | 5 |
Schedule 1, after entry for Degarelix
insert in the columns in the order indicated:
| Denosumab | Injection 120 mg in 1.7 mL | Injection | 1 | 5 |
Schedule 1, after entry for Imatinib
insert in the columns in the order indicated:
| Indacaterol | Capsule containing powder for oral inhalation 150 micrograms (as maleate) (for use in Breezhaler) | Inhalation by mouth | 30 | 5 |
| Capsule containing powder for oral inhalation 300 micrograms (as maleate) (for use in Breezhaler) | Inhalation by mouth | 30 | 5 |
Schedule 1, after entry for Lisinopril
insert in the columns in the order indicated:
| Losartan | Tablet containing losartan potassium 25 mg | Oral | 30 | 5 |
| Tablet containing losartan potassium 50 mg | Oral | 60 | 5 |
Schedule 1, after entry for Pindolol
insert in the columns in the order indicated:
| Pramipexole | Tablet (extended release) containing pramipexole hydrochloride 1.5 mg | Oral | 30 | 5 |
| Tablet (extended release) containing pramipexole hydrochloride 2.25 mg | Oral | 30 | 5 | |
| Tablet (extended release) containing pramipexole hydrochloride 3 mg | Oral | 30 | 5 | |
| Tablet (extended release) containing pramipexole hydrochloride 3.75 mg | Oral | 30 | 5 | |
| Tablet (extended release) containing pramipexole hydrochloride 4.5 mg | Oral | 30 | 5 |
1Note
All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003.
See
0
0
0